A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia

被引：1
|
作者：
Shah, Bijal D. [1 ]
Rozario, Nicole [2 ]
Turba, Elyce P. [3 ]
Bello, Celeste [4 ]
Chavez, Julio C. [3 ]
Sokol, Lubomir [4 ]
Brayer, Jason [5 ]
Lancet, Jeffrey E. [6 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-151936
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4399
引用
收藏
页数：4
相关论文
共 50 条
  • [31] A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia
    Klisovic, Rebecca B.
    Leung, Wing H.
    Brugger, Wolfram
    Dirnberger-Hertweck, Maren
    Winderlich, Mark
    Ambarkhane, Sumeet V.
    Jabbour, Elias J.
    CANCER, 2021, 127 (22) : 4190 - 4197
  • [32] A phase I/pilot study of CPX-351 for children, adolescents and young adults with recurrent or refractory hematologic malignancies.
    Absalon, Michael
    O'Brien, Maureen Megan
    Phillips, Christine L.
    Burns, Karen Cristly
    Mangino, Jennifer
    Mizukawa, Benjamin
    Breese, Erin Haag
    Shah, Rachana
    Perentesis, John Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
    Shah, Bijal D.
    Ghobadi, Armin
    Oluwole, Olalekan O.
    Logan, Aaron C.
    Boissel, Nicolas
    Cassaday, Ryan D.
    Leguay, Thibaut
    Bishop, Michael R.
    Topp, Max S.
    Tzachanis, Dimitrios
    O'Dwyer, Kristen M.
    Arellano, Martha L.
    Lin, Yi
    Baer, Maria R.
    Schiller, Gary J.
    Park, Jae H.
    Subklewe, Marion
    Abedi, Mehrdad
    Minnema, Monique C.
    Wierda, William G.
    DeAngelo, Daniel J.
    Stiff, Patrick
    Jeyakumar, Deepa
    Feng, Chaoling
    Dong, Jinghui
    Shen, Tong
    Milletti, Francesca
    Rossi, John M.
    Vezan, Remus
    Masouleh, Behzad Kharabi
    Houot, Roch
    LANCET, 2021, 398 (10299): : 491 - 502
  • [34] Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
    Younes, Anas
    Oki, Yasuhiro
    Bociek, R. Gregory
    Kuruvilla, John
    Fanale, Michelle
    Neelapu, Sattva
    Copeland, Amanda
    Buglio, Daniela
    Galal, Ahmed
    Besterman, Jeffrey
    Li, Zuomei
    Drouin, Michel
    Patterson, Tracy
    Ward, M. Renee
    Paulus, Jessica K.
    Ji, Yuan
    Medeiros, L. Jeffrey
    Martell, Robert E.
    LANCET ONCOLOGY, 2011, 12 (13): : 1222 - 1228
  • [35] Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
    Ma, Xinran
    Li, Ling
    Zhang, Lei
    Fu, Xiaorui
    Li, Xin
    Wang, Xinhua
    Wu, Jingjing
    Sun, Zhenchang
    Zhang, Xudong
    Feng, Xiaoyan
    Chang, Yu
    Zhou, Zhiyuan
    Nan, Feifei
    Zhang, Jieming
    Li, Zhaoming
    Zhang, Mingzhi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 275 - 284
  • [36] Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial
    Kroiss, Matthias
    Quinkler, Marcus
    Johanssen, Sarah
    van Erp, Nielka P.
    Lankheet, Nienke
    Poellinger, Alexander
    Laubner, Katharina
    Strasburger, Christian J.
    Hahner, Stefanie
    Mueller, Hans-Helge
    Allolio, Bruno
    Fassnacht, Martin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (10): : 3495 - 3503
  • [37] Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
    Holger N. Lode
    Karoline Ehlert
    Stephanie Huber
    Sascha Troschke-Meurer
    Nikolai Siebert
    Maxi Zumpe
    Hans Loibner
    Ruth Ladenstein
    British Journal of Cancer, 2023, 129 : 1780 - 1786
  • [38] Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
    Lode, Holger N.
    Ehlert, Karoline
    Huber, Stephanie
    Troschke-Meurer, Sascha
    Siebert, Nikolai
    Zumpe, Maxi
    Loibner, Hans
    Ladenstein, Ruth
    BRITISH JOURNAL OF CANCER, 2023, 129 (11) : 1780 - 1786
  • [39] Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
    Jerkeman, Mats
    Eskelund, Christian Winther
    Hutchings, Martin
    Raty, Riikka
    Wader, Karin Fahl
    Laurell, Anna
    Toldbod, Helle
    Pedersen, Lone Bredo
    Niemann, Carsten Utoft
    Dahl, Christina
    Kuitunen, Hanne
    Geisler, Christian H.
    Gronbaek, Kirsten
    Kolstad, Arne
    LANCET HAEMATOLOGY, 2018, 5 (03): : E109 - E116
  • [40] Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial
    Liu, Yanyan
    Lin, Ningjing
    Yi, Shuhua
    Huang, Huiqiang
    Guo, Ye
    Zhang, Qingyuan
    Yang, Haiyan
    Zhang, Huilai
    Zhang, Liling
    Feng, Ru
    Qian, Yijiao
    Zhu, Jiankun
    Song, Yuqin
    Zhu, Jun
    INTERNATIONAL JOURNAL OF CANCER, 2025,
12345